Table. 1 Baseline characteristics of the patients before and after PSM

From: Artificial intelligence-based personalized treatment strategies for unresectable hepatocellular carcinoma: integrating HSP90α for prognosis and survival prediction

  

Before PSM

 

After PSM

 

Variable

ALL

No TACE

TACE

P

No TACE

TACE

P

N (%)

N (%)

N (%)

N (%)

Patients

2555

1126

1429

 

666

666

 

Male sex

2049 (80.2)

858 (76.2)

1191 (83.3)

 

546 (82.0)

544 (81.7)

 

Age ≥ 65 years

666 (26.1)

339 (30.1)

327 (22.9)

<0.001

184 (27.6)

175 (26.3)

0.621

HSP90α (mean ± SD, ng/mL)

158 ± 118

158 ± 121

157 ± 116

0.930

156 ± 121

151 ± 114

0.385

HBV

1397 (54.7)

518 (46.0)

879 (61.5)

<0.001

360 (54.1)

374 (56.2)

0.474

Diabetes mellitus

240 (9.39)

126 (11.2)

114 (7.98)

0.007

66 (9.91)

68 (10.2)

0.927

Hypertension

360 (14.1)

163 (14.5)

197 (13.8)

0.660

101 (15.2)

104 (15.6)

0.879

Child

   

<0.001

  

0.721

A

1753 (68.6)

678 (60.2)

1075 (75.2)

 

466 (70.0)

459 (68.9)

 

B

802 (31.4)

448 (39.8)

354 (24.8)

 

200 (30.0)

207 (31.1)

 

ALBI grade

   

<0.001

  

0.728

1

656 (25.7)

281 (25.0)

375 (26.2)

 

169 (25.4)

180 (27.0)

 

2

1627 (63.7)

643 (57.1)

984 (68.9)

 

444 (66.7)

438 (65.8)

 

3

272 (10.6)

202 (17.9)

70 (4.90)

 

53 (7.96)

48 (7.21)

 

AFP ≥ 400 ng/mL

1238 (48.5)

462 (41.0)

776 (54.3)

<0.001

311 (46.7)

299 (44.9)

0.545

ALP ≥ 125 U/L

1557 (60.9)

721 (64.0)

836 (58.5)

0.005

400 (60.1)

399 (59.9)

1.000

Platelet ≥ 100×109/L

1822 (71.3)

817 (72.6)

1005 (70.3)

0.233

475 (71.3)

472 (70.9)

0.904

ALT levels ≥ 40 U/L

1356 (53.1)

630 (56.0)

726 (50.8)

0.011

347 (52.1)

358 (53.8)

0.583

Leukocyte ≥ 4× 109/L

2099 (82.2)

944 (83.8)

1155 (80.8)

0.055

539 (80.9)

548 (82.3)

0.572

BCLC

   

<0.001

  

0.738

A

386 (15.1)

198 (17.6)

188 (13.2)

 

105 (15.8)

109 (16.4)

 

B

485 (19.0)

154 (13.7)

331 (23.2)

 

114 (17.1)

123 (18.5)

 

C

1684 (65.9)

774 (68.7)

910 (63.7)

 

447 (67.1)

434 (65.2)

 

Tumor number ≥ 2

1977 (77.4)

838 (74.4)

1139 (79.7)

0.002

511 (76.7)

514 (77.2)

0.896

Tumor size, cm

   

<0.001

  

0.836

< 3

328 (12.8)

175 (15.5)

153 (10.7)

 

91 (13.7)

87 (13.1)

 

≥3, <5

546 (21.4)

295 (26.2)

251 (17.6)

 

156 (23.4)

160 (24.0)

 

≥5, <10

955 (37.4)

423 (37.6)

532 (37.2)

 

246 (36.9)

258 (38.7)

 

≥10

726 (28.4)

233 (20.7)

493 (34.5)

 

173 (26.0)

161 (24.2)

 

PVTT

985 (38.6)

391 (34.7)

594 (41.6)

<0.001

265 (39.8)

252 (37.8)

0.500

N

1248 (48.8)

568 (50.4)

680 (47.6)

0.163

332 (49.8)

320 (48.0)

0.547

M

642 (25.1)

349 (31.0)

293 (20.5)

<0.001

173 (26.0)

162 (24.3)

0.528

  1. PSM propensity score matching, HSP90α heat-shock protein 90α, HBV hepatitis B virus, ALBI albumin–bilirubin, AFP alpha fetoprotein, ALP alkaline phosphatase, ALT alanine ami notransferase, PVTT portal vein tumor thrombus, TACE transcatheter arterial chemoembolization.
Back to article page